JLL vs SUPN · P/E 23, rev $13.31B vs rev $426.8M
Jones Lang LaSalle Incorporated (JLL) versus Supernus Pharmaceuticals Inc (SUPN) — a side-by-side from cached financials, not a winner call.
Jones Lang LaSalle Incorporated (JLL) is a real estate services company listed on US.
Supernus Pharmaceuticals Inc (SUPN) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported JLL revenue for 2026-06-30 was $13.31B. Net income was $373.7M. JLL currently screens at market cap $12.12B and trailing P/E 23.0.
Latest reported SUPN revenue for 2026-06-30 was $426.8M. Net income was -$60.7M. SUPN currently screens at market cap $2.53B.
JLL currently screens at market cap $12.12B and trailing P/E 23.0. SUPN currently screens at market cap $2.53B.
Not investment advice. Open the JLL and SUPN stock pages for the full models.
Not investment advice.